Tue Sep 23 20:19:33 SGT 2014  
    Quit Smoking, SG /

Quit Smoking, SG /


Quit Smoking, SG / @beauty_sg: Quit/stop smoking with the medication Champix«. Smoking cessation clinic, SG / . Private and confidential services. Definitions, references, and latest news.

Keywords: Quit Smoking SG / , SG / Quit Smoking, Quit Smoking.


Quit smoking with the medication Champix®. Revolutionary new way to stop smoking at our smoking cessation clinic. Get away from the harmful effects of smoking, without feeling the effects of withdrawal!

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Quit Smoking, SG /
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Table of Contents
Mon, 22 Sep 2014 20:13:17 +0100 | The Brown University Psychopharmacology Update

Varenicline and Cardiovascular Adverse EventsVarenicline and Cardiovascular Adverse Events
Mon, 22 Sep 2014 10:16:21 +0100 | Medscape Today Headlines
How strong is the evidence suggesting that varenicline is cardiotoxic? Read this review to find out. Therapeutic Advances in Drug Safety (Source: Medscape Today Headlines)

Searching for phenotypes in smoking cessation treatment
Fri, 19 Sep 2014 00:00:00 +0100 | International Journal of Clinical Practice
ConclusionIt was possible to identify several smoking phenotypes in which different treatments have different efficacies. (Source: International Journal of Clinical Practice)

{alpha}7/dup{alpha}7 and {alpha}7/dup{Delta}{alpha}7 Heteropentameric nAChRs [Cell Biology]
Thu, 18 Sep 2014 00:00:00 +0100 | Journal of Biological Chemistry
The ╬▒7 nicotinic acetylcholine receptor gene (CHRNA7) is linked to schizophrenia. A partial duplication of CHRNA7 (CHRFAM7A) is found in humans on 15q13ÔÇô14. Exon 6 of CHRFAM7A harbors a 2-bp deletion polymorphism, CHRFAM7A╬ö2bp, which is also associated with schizophrenia. To understand the effects of the duplicated subunits on ╬▒7 receptors, we fused ╬▒7, dup╬▒7, and dup╬ö╬▒7 subunits with various fluorescent proteins. The duplicated subunits co-localized with full-length ╬▒7 subunits in mouse neuroblastoma cells (Neuro2a) as well as rat hippocampal neurons. We investigated the interaction between the duplicated subunits and full-length ╬▒7 by measuring F├Ârster resonance energy transfer using donor recovery after photobleaching and fluorescence lifetime imaging microscopy. The results...

The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.
Thu, 28 Aug 2014 00:00:00 +0100 | Neuropharmacology
Authors: Thompson AJ, Verheij MH, Verbeek J, Windhorst AD, de Esch IJ, Lummis SC

CHANTIX (Varenicline Tartrate) Tablet, Film Coated [Carilion Materials Management]
Wed, 20 Aug 2014 05:00:00 +0100 | DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)
Updated Date: Aug 20, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Permeability Analysis of Neuroactive Drugs Through a Dynamic Microfluidic In Vitro Blood-Brain Barrier Model.
Wed, 13 Aug 2014 00:00:00 +0100 | Annals of Biomedical Engineering
Authors: Booth R, Kim H

Culturally Tailored Smoking Cessation for Adult American Indian Smokers: A Clinical Trial
Tue, 05 Aug 2014 00:00:00 +0100 | The Counseling Psychologist
This collaborative, community-engaged project developed and tested a Culturally Tailored Treatment (CTT) for American Indian/Alaska Native (AI/AN) smokers in the Menominee tribal community. One hundred three adult AI/AN smokers were randomized to receive either Standard Treatment (ST; n = 53) or CTT (n = 50) for smoking cessation. Both treatment conditions included 12 weeks of varenicline and four individual counseling sessions but differed in terms of cultural tailoring of the counseling. The primary outcome was 7-day, biochemically confirmed point-prevalence abstinence (PPA) at the 6-month end-of-study visit. Both intention-to-treat (ITT) and responder-only analyses were conducted. There were no statistically significant group differences in 7-day PPA. The overall ITT abstinence rate at ...

Varenicline in the Treatment of Alcohol Use Disorders.
Tue, 05 Aug 2014 00:00:00 +0100 | The Annals of Pharmacotherapy
CONCLUSIONS: Evidence supports the use of varenicline for the reduction of alcohol craving as well as for the reduction of overall alcohol consumption in patients with alcohol use disorders. However, it is not likely to improve abstinence rates. Although most of the data were derived from patients with concurrent nicotine dependence, the effects of varenicline appear to occur independent of baseline smoking status.

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.
Fri, 25 Jul 2014 00:00:00 +0100 | The American Journal of Drug and Alcohol Abuse
Conclusions: These preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers. AEs were consistent with those typically reported for VAR and NAC. These data support future efficacy research on NAC and VAR for smoking cessation.